The diabetes team at Abbott has issued a press release today, stating that their FreeStyle Libre 2 iCGM has been cleared in the US for adults and children with diabetes, achieving what they are highlighting as the highest levels of accuracy and performance standards.
“We’re thrilled to bring our next generation technology on our world-leading sensing platform to both children and adults with diabetes in the U.S.,” said Jared Watkin, senior vice president, Diabetes Care, Abbott in today’s release. “With unsurpassed 14-day accuracy and enhanced features including optional alarms at a fraction of the cost of other CGMs, Abbott’s FreeStyle Libre 2 system will change the future of diabetes care in the U.S. the same way it has around the globe.”
Details from today’s press release include:
- Only iCGM that measures glucose every minute, meeting the highest level of accuracy standards.2 Every minute counts when it comes to managing diabetes. The FreeStyle Libre 2 system measures every minute, five times more often than other CGMs.3,4
- Longest lasting self-applied sensor. At 14 days, FreeStyle Libre 2 is the longest-lasting iCGM available, nearly 40 percent longer than the other iCGM. And with its built-in shutoff at 14 days, you can trust in its reliability. Simply, it’s unsurpassed 14-day accuracy1.
- Now for kids 4 and up. That’s right. With U.S. Food and Drug Administration clearance, FreeStyle Libre 2 can be prescribed for children 4 and older with diabetes once available, broadening the impact of this revolutionary technology.
- A third of the cost. More features, excellent accuracy, significantly lower cost.5 Compared to other CGMs, the FreeStyle Libre 2 system will cost 70% less.
- Customizable, optional real-time alarms. You’ll know within a minute when your glucose has veered too far from where it should be. Alarms automatically alert you if you’re too high or too low without having to scan.
- Fewer false alarms for kids 4 and up. The next generation of the FreeStyle Libre technology reduces false alarms for kids by a third compared with the other iCGM available6 in the U.S.
CWD’s President, Jeff Hitchcock, said, “The FDA’s approval of Libre 2 for adults and kids with type 1 diabetes is great news, giving families more choices when it comes to managing diabetes. As always, the CWD community looks forward to even more innovation in CGM technology as we celebrate today’s announcement.”
For a PDF with downloadable information about the Libre 2, you can view that here. And, as always, you can keep up with the latest in diabetes research and technology by subscribing to our What’s New newsletter.